- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Family's Fight for Meningitis B Vaccine Access After Tragic Loss
Meg Draper's death sparks crucial conversation about vaccine eligibility and public health
Apr. 12, 2026 at 2:44pm
Got story updates? Submit your updates here. ›
A haunting X-ray image reveals the delicate inner workings of the human brain, underscoring the urgent need for greater access to life-saving meningitis vaccines.Auburn TodayThe tragic story of Meg Draper, an 18-year-old student who lost her life to Meningitis B, has sparked a crucial conversation about vaccine accessibility and public health. Meg's parents, Helen and Lee Draper, fear that without a wider rollout of the MenB vaccine, similar outbreaks could occur again. This case highlights a gap in the healthcare system and raises important questions about vaccine eligibility and the potential consequences of limited access.
Why it matters
Meningitis B is a rare but deadly strain of meningitis. While the MenACWY vaccine is offered to teenagers in England and Wales, the MenB vaccine is only available on the NHS for young children born after 2015. This means that older children and adults are left vulnerable, with a private MenB vaccine or booster costing around £220. The JCVI, a scientific advisory committee, concluded in 2014 that vaccinating teenagers and young adults against MenB was not cost-effective. However, as Meg's story shows, the consequences of this decision can be devastating.
The details
In the aftermath of Meg's death, the University of Bournemouth held meningitis vaccination clinics, but the MenB vaccine was not offered. Helen expressed concern about the misinformation and lack of guidance, stating that students naturally assumed they were protected. The UKHSA defended their decision, stating that Meg's death was a single case and that they fully complied with their guidance. However, Helen and Lee argue that the confusion surrounding MenB stems from a lack of clear information and guidance, which has persisted for years.
- Meg Draper, an 18-year-old student, tragically lost her life to Meningitis B.
- The University of Bournemouth held meningitis vaccination clinics following Meg's death, but the MenB vaccine was not offered.
The players
Meg Draper
An 18-year-old student who lost her life to Meningitis B.
Helen Draper
Meg's mother, who is advocating for wider access to the MenB vaccine.
Lee Draper
Meg's father, who is advocating for wider access to the MenB vaccine.
JCVI
A scientific advisory committee that concluded in 2014 that vaccinating teenagers and young adults against MenB was not cost-effective.
Dr. Mary Ramsay
A representative of the UKHSA who emphasizes the importance of early treatment and encourages parents to be aware of the symptoms of Meningitis B.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee
What’s next
The Welsh government has asked the JCVI to reexamine eligibility for meningitis vaccines in light of the Kent outbreak. Political parties in Wales are also calling for action, urging the government to extend MenB vaccine access to older teenagers and university students.
The takeaway
The MenB vaccine debate highlights a larger issue of vaccine accessibility and public health. While cost-effectiveness is an important consideration, the potential cost of human lives must also be weighed. As Helen and Lee's campaign for awareness shows, there is a need for clearer information and guidance on MenB. The JCVI's review of vaccine eligibility is a step in the right direction, but swift action is required to prevent further tragedies.


